Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urology Journal Pub Date : 2024-06-12 DOI:10.22037/uj.v21i.8119

Ki Mun Kang, Hun Sik Choi, Hong Seok Jang, Jin-Ho Song

{"title":"Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency.","authors":"Ki Mun Kang, Hun Sik Choi, Hong Seok Jang, Jin-Ho Song","doi":"10.22037/uj.v21i.8119","DOIUrl":null,"url":null,"abstract":"Purpose: Prostate-specific antigen (PSA) bounce is a common phenomenon that can be observed in patients of prostate cancer treated by radiotherapy. However, the clinical, pathological, or dosimetric predictors and clinical significance of PSA bounce in stereotactic body radiotherapy (SBRT) patients is still unknown.Methods: Between August 2006 to December 2015, 74 prostate cancer patients were treated by SBRT with Cyberknife at two medical centers. The prescription dose was 35-37.5 Gy in 5 fractions. Follow-up PSA tests were more frequently performed in one hospital than the other (median 4 vs. 10 times for initial one year). PSA bounce was defined as a rise of 0.2 ng/mL followed by a decline to or below previous nadir.Results: A total of 74 patients, PSA bounce was observed in 41 patients (55.4%). On univariate analysis, the treated medical center (p = 0.02), PSA follow-up frequency (p = 0.01), patient age (p < 0.01), and total prescription dose (p = 0.03) were significant clinical factors to predict the incidence of PSA bounce, while in multivariable analysis only the PSA follow-up frequency, and patient age remains significant.Conclusion: PSA bounce was seen in a significant proportion of patients after Cyberknife SBRT. The PSA follow-up test frequency, and patient age were significant factors that were correlated with the incidence of PSA bounces in this study.","PeriodicalId":23416,"journal":{"name":"Urology Journal","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22037/uj.v21i.8119","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Prostate-specific antigen (PSA) bounce is a common phenomenon that can be observed in patients of prostate cancer treated by radiotherapy. However, the clinical, pathological, or dosimetric predictors and clinical significance of PSA bounce in stereotactic body radiotherapy (SBRT) patients is still unknown.

Methods: Between August 2006 to December 2015, 74 prostate cancer patients were treated by SBRT with Cyberknife at two medical centers. The prescription dose was 35-37.5 Gy in 5 fractions. Follow-up PSA tests were more frequently performed in one hospital than the other (median 4 vs. 10 times for initial one year). PSA bounce was defined as a rise of 0.2 ng/mL followed by a decline to or below previous nadir.

Results: A total of 74 patients, PSA bounce was observed in 41 patients (55.4%). On univariate analysis, the treated medical center (p = 0.02), PSA follow-up frequency (p = 0.01), patient age (p < 0.01), and total prescription dose (p = 0.03) were significant clinical factors to predict the incidence of PSA bounce, while in multivariable analysis only the PSA follow-up frequency, and patient age remains significant.

Conclusion: PSA bounce was seen in a significant proportion of patients after Cyberknife SBRT. The PSA follow-up test frequency, and patient age were significant factors that were correlated with the incidence of PSA bounces in this study.

查看原文本刊更多论文

前列腺癌立体定向体外放射治疗后前列腺特异性抗原（PSA）的反弹：PSA检测频率的重要性。

目的：前列腺特异性抗原（PSA）反跳是放射治疗前列腺癌患者中常见的一种现象。然而，立体定向体放射治疗（SBRT）患者PSA反跳的临床、病理或剂量学预测因素和临床意义尚不清楚：2006年8月至2015年12月期间，两家医疗中心使用赛博刀对74名前列腺癌患者进行了SBRT治疗。处方剂量为35-37.5 Gy，分5次进行。一家医院比另一家医院更频繁地进行PSA随访检测（最初一年的中位数为4次，而另一家医院为10次）。PSA反弹的定义是上升0.2纳克/毫升，然后下降到或低于之前的最低点：共有 74 名患者，其中 41 名患者（55.4%）出现 PSA 反弹。在单变量分析中，接受治疗的医疗中心（P = 0.02）、PSA 随访频率（P = 0.01）、患者年龄（P < 0.01）和处方总剂量（P = 0.03）是预测 PSA 反弹发生率的重要临床因素，而在多变量分析中，只有 PSA 随访频率和患者年龄仍具有重要意义：结论：射波刀 SBRT 治疗后，有相当一部分患者出现 PSA 反弹。本研究中，PSA随访测试频率和患者年龄是与PSA反弹发生率相关的重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urology Journal UROLOGY & NEPHROLOGY-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： As the official journal of the Urology and Nephrology Research Center (UNRC) and the Iranian Urological Association (IUA), Urology Journal is a comprehensive digest of useful information on modern urology. Emphasis is on practical information that reflects the latest diagnostic and treatment techniques. Our objectives are to provide an exceptional source of current and clinically relevant research in the discipline of urology, to reflect the scientific work and progress of our colleagues, and to present the articles in a logical, timely, and concise format that meets the diverse needs of today’s urologist. Urology Journal publishes manuscripts on urology and kidney transplantation, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. Accordingly, original articles, case reports, and letters to editor are encouraged.